Real-World Comparative Analysis of Polatuzumab Vedotin-Based Pola-R-CHP Versus Standard R-CHOP in Diffuse Large B-Cell Lymphoma: A Propensity Score-Matched Cohort Study
{{output}}
Introduction The regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) remains the standard first-line treatment for diffuse large B-cell lymphoma (DLBCL), yet many patients relapse. Polatuzumab vedotin combined with rituxim... ...
